Drug manufacturers to focus on China and Japan, where penetration is low and innovation continues to emerge, Morgan Stanley ...

But this one, for Lilly’s first diabetes and weight-loss pill based on the GLP-1 hormone, was particularly fraught. Days ...

Eli Lilly stock ... a diabetes drug also used for weight loss. The positive data gives the company the green light to file the drug with the Food and Drug Administration for approval.

It used to be that Chinese drug development was largely about creating "me too" drugs for the local market. But over the past ...

Some drugs initially approved to treat Type ... Elizabeth Smelov The first GLP-1 weight-loss pill is a step closer to hitting the market. Eli Lilly said its experimental pill met its goals in ...

Less than five years on from when Novo Nordisk's semaglutide drug received FDA approval for weight ... of delivering far superior weight loss compared to Lilly's Mounjaro, the company is likely ...

Eli Lilly, the drugmaker behind the blockbuster weight loss drug Zepbound ... telehealth company improperly referenced Lilly's approved drugs and clinical trials on its website in order to ...

Eli Lilly’s stock wobbled Thursday after a looming coverage hit was detailed for its blockbuster weight-loss drug Zepbound.

The market for weight-loss drugs could see new entrants among existing biotech firms, with several drug candidates likely to be approved for ... particularly in China and Japan, where penetration ...